InSilico Medicine
Hematopoietic progenitor kinase 1 (HPK1), a member of the Ste20 serine/threonine kinases family, negatively regulates T cell function and is considered a promising target for immunotherapy. Despite the promising efficacy demonstrated in preclinical models, no HPK1 inhibitors are currently approved for clinical use, due to challenges including balance between kinase selectivity and pharmacokinetic properties.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
